MedPath

Deferasirox

Generic Name
Deferasirox
Brand Names
Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan
Drug Type
Small Molecule
Chemical Formula
C21H15N3O4
CAS Number
201530-41-8
Unique Ingredient Identifier
V8G4MOF2V9
Background

Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication

For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions
Chronic Iron Overload
Associated Therapies
-

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Interventions
Drug: Placebo
Drug: Deferasirox
First Posted Date
2009-07-16
Last Posted Date
2020-11-23
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
225
Registration Number
NCT00940602
Locations
🇺🇸

Willis-Knighton Cancer Center Dept of Onc, Shreveport, Louisiana, United States

🇺🇸

Hackensack University Medical Center Department of Research, Hackensack, New Jersey, United States

🇺🇸

Rocky Mountain Cancer Centers RMCC, Greenwood Village, Colorado, United States

and more 9 locations

Effect of Deferasirox on Patients With Cardiac MRI T2* < 20 Msec

Phase 2
Completed
Conditions
Beta Thalassemia Transfusion Dependent
Interventions
First Posted Date
2009-04-09
Last Posted Date
2016-12-12
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT00879242
Locations
🇮🇹

Novartis Investigative Site, Orbassano, Italy

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

Phase 2
Completed
Conditions
Non-transfusion Dependent Thalassemia
Interventions
Drug: deferasirox
Drug: placebo
First Posted Date
2009-04-01
Last Posted Date
2013-07-09
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
166
Registration Number
NCT00873041
Locations
🇺🇸

Children's Memorial Hospital/Division of Hematology/Oncology, Chicago, Illinois, United States

🇺🇸

New York Presbyterian Hospital/Weill Medical College of Cornell University, New York, New York, United States

🇺🇸

Children's Hospital & Research Center Oakland, Oakland, California, United States

and more 1 locations

Pilot Study for Patients With Poor Response to Deferasirox

Phase 4
Completed
Conditions
Transfusion-dependent Hemachromatosis
Sickle Cell Disease
Thalassemia Major
Interventions
First Posted Date
2008-09-09
Last Posted Date
2024-02-12
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
15
Registration Number
NCT00749515
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Phase 1
Conditions
Thalassemia
Interventions
First Posted Date
2008-08-20
Last Posted Date
2010-11-05
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
6
Registration Number
NCT00738413
Locations
🇺🇸

Weill Cornell Medical Center, New York, New York, United States

Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload

Phase 4
Completed
Conditions
Hemoglobinopathies
Myelodysplastic Syndromes
Other Inherited or Acquired Anaemia
MPD Syndrome
Diamond-Blackfan Anemia
Other Rare Anaemias
Transfusional Iron Overload
Interventions
First Posted Date
2008-05-07
Last Posted Date
2017-02-23
Lead Sponsor
Novartis
Target Recruit Count
118
Registration Number
NCT00673608
Locations
🇦🇺

Novarts Investigative Site, Sydney, Australia

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

Phase 4
Completed
Conditions
Iron Overload
Interventions
First Posted Date
2008-04-08
Last Posted Date
2016-11-17
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
75
Registration Number
NCT00654589
Locations
🇩🇪

Novartis Investigative Site, Leipzig, Germany

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

Phase 2
Terminated
Conditions
Breast Cancer
Iron Overload
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Neuroblastoma
Ovarian Cancer
Interventions
First Posted Date
2008-01-28
Last Posted Date
2017-12-28
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
4
Registration Number
NCT00602446
Locations
🇺🇸

Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Phase 2
Completed
Conditions
Transfusional Iron Overload
Transfusional Hemosiderosis
Interventions
First Posted Date
2008-01-25
Last Posted Date
2014-08-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
197
Registration Number
NCT00600938
Locations
🇬🇧

Novartis Investigative Site, London, United Kingdom

Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda

Phase 3
Completed
Conditions
Porphyria Cutanea Tarda
Interventions
First Posted Date
2008-01-23
Last Posted Date
2014-02-10
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
10
Registration Number
NCT00599326
Locations
🇺🇸

UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath